Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
RLAY - Relay Therapeutics Inc
4.17(7.36%)7:43:54 PM 1/22/2021
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Stock Chart


  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
  • MACD is crossing MACD signal line at 2.0. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics

Stock news

    We Think Relay Therapeutics (NASDAQ:RLAY) Can Easily Afford To Drive Business Growth

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

    SoftBank’s Son Is Poised for Another IPO Windfall in 2021

    (Bloomberg) -- SoftBank Group Corp. is preparing to take at least six more of its portfolio companies public this year, building on a 2020 turnaround that pushed the value of Masayoshi Son’s technology conglomerate to the highest since the dot-com boom.Among the startups heading for initial public offerings are South Korean e-commerce pioneer Coupang Corp., Indonesian online mall operator PT Tokopedia and China’s ride-hailing giant Didi Chuxing, according to people familiar with the matter, aski...

    Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. ET. The presentation will be webcast live and may be accessed from the Investor page of Relay’s website under Events and Presentations. An archived replay of the webcast will be available for at least 30 days following the presentation. About Relay TherapeuticsRelay Therapeutics (Nasdaq:...

    Is RLAY A Good Stock To Buy Now?

    In this article we will analyze whether Relay Therapeutics, Inc. (NASDAQ:RLAY) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

    Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971

    Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and $695 million in additional potential milestones, plus royalties on global net product sales Relay Therapeutics to host conference call at 8:00 a.m. ETCAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company tran...

    Relay Therapeutics Reports Third Quarter 2020 Financial Results

    CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported third quarter 2020 financial results. “In our first quarter as a public company, I am proud of our team’s unwavering focus on bringing our medicines to patients,” said Sanjiv Patel, M.D., president and chief executive officer of Relay Therapeutics. “...

    Are Insiders Buying Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...